Applied Therapeutics, Inc.

NasdaqGM:APLT Stock Report

Market Cap: US$48.8m

Applied Therapeutics Management

Management criteria checks 1/4

Applied Therapeutics' CEO is Les Funtleyder, appointed in Nov 2023, has a tenure of 1.58 years. total yearly compensation is $1.05M, comprised of 50.4% salary and 49.6% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth $72.73K. The average tenure of the management team and the board of directors is 1.3 years and 6.2 years respectively.

Key information

Les Funtleyder

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage50.35%
CEO tenure1.6yrs
CEO ownership0.1%
Management average tenure1.3yrs
Board average tenure6.2yrs

Recent management updates

Recent updates

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Nov 15
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Sep 18

Applied Therapeutics: Pushing Towards FDA Approval

Sep 04

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Aug 01
We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

May 28

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Feb 16

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Feb 16
Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Nov 13
Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Aug 11
We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

May 19
We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Jan 19

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Nov 11
Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Aug 13
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

May 15
Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Feb 26
Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Feb 18
How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

CEO Compensation Analysis

How has Les Funtleyder's remuneration changed compared to Applied Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$44m

Dec 31 2024US$1mUS$531k

-US$106m

Sep 30 2024n/an/a

-US$187m

Jun 30 2024n/an/a

-US$161m

Mar 31 2024n/an/a

-US$194m

Dec 31 2023US$675kn/a

-US$120m

Sep 30 2023n/an/a

-US$97m

Jun 30 2023n/an/a

-US$73m

Mar 31 2023n/an/a

-US$70m

Dec 31 2022US$80kn/a

-US$83m

Sep 30 2022n/an/a

-US$95m

Jun 30 2022n/an/a

-US$105m

Mar 31 2022n/an/a

-US$105m

Dec 31 2021US$229kn/a

-US$106m

Sep 30 2021n/an/a

-US$102m

Jun 30 2021n/an/a

-US$104m

Mar 31 2021n/an/a

-US$106m

Dec 31 2020US$303kn/a

-US$94m

Sep 30 2020n/an/a

-US$88m

Jun 30 2020n/an/a

-US$69m

Mar 31 2020n/an/a

-US$49m

Dec 31 2019US$625kn/a

-US$46m

Sep 30 2019n/an/a

-US$35m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$30kn/a

-US$17m

Compensation vs Market: Les's total compensation ($USD1.05M) is above average for companies of similar size in the US market ($USD643.62K).

Compensation vs Earnings: Les's compensation has increased whilst the company is unprofitable.

CEO

Les Funtleyder (55 yo)

1.6yrs
Tenure
US$1,053,846
Compensation

Mr. Les D. Funtleyder has been an Independent Director of Reviva Pharmaceuticals Holdings, Inc. since December 8, 2020. Mr. Funtleyder served as Interm CEO, CFO, Principal Financial Officer & Independent D...

Leadership Team

NamePositionTenureCompensationOwnership
John Johnson
Executive Chairmanless than a yearUS$3.19mno data
Les Funtleyder
Interm CEO1.6yrsUS$1.05m0.15%
$ 72.7k
Corwin Hooks
Chief Commercial Officer1.2yrsUS$2.18m0.057%
$ 28.0k
Constantine Chinoporos
COO & Chief Business Officer1.5yrsno data0.055%
$ 26.8k
Catherine Thorpe
Interim Chief Accounting Officer2yrsno datano data
Riccardo Perfetti
Chief Medical Officer6.8yrsUS$3.04m0.25%
$ 121.6k
Reena Colacot
Head of Qualityless than a yearno datano data
Todd Baumgartner
Chief Regulatory Officerless than a yearno datano data
1.3yrs
Average Tenure
60yo
Average Age

Experienced Management: APLT's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
John Johnson
Executive Chairmanless than a yearUS$3.19mno data
Les Funtleyder
Interm CEO9yrsUS$1.05m0.15%
$ 72.7k
Jay Skyler
Independent Director6.2yrsUS$267.50k0.038%
$ 18.5k
Lawrence Steinman
Member of Scientific Advisory Boardno datano datano data
Teena Lerner
Lead Independent Director8.3yrsUS$265.00k0.074%
$ 36.4k
Stacy Kanter
Independent Director6.1yrsUS$267.50k0.076%
$ 37.3k
Gregg Stone
Member of Scientific Advisory Boardno datano datano data
Donald Landry
Chairman of Scientific Advisory Boardno datano datano data
Donald D'Amico
Member of Scientific Advisory Boardno datano datano data
Roy Freeman
Member of Scientific Advisory Boardno datano datano data
Roxana Mehran
Member of Scientific Advisory Boardno datano datano data
6.2yrs
Average Tenure
68yo
Average Age

Experienced Board: APLT's board of directors are considered experienced (6.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/18 15:38
End of Day Share Price 2025/06/18 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Applied Therapeutics, Inc. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Carter GouldBarclays
Paul ChoiGoldman Sachs